# US 2025/0304588 A1 · Process for preparing beta 3 agonists and intermediates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0304588 A1
- Document ID: US20250304588A1
- Status: Published application
- Kind: A1
- Application number: 19/003,660
- Filed: 2024-12-27
- Published: 2025-10-02
- Earliest claimed: 2013-03-15
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme LLC
- Inventors: Feng XU; Zhuqing LIU; Richard DESMOND; Jeonghan PARK; Alexei KALININ; Birgit KOSJEK; Hallena STROTMAN; Hongmei LI; Johannah MONCECCHI
- Web page: https://patentgrep.com/patent/US20250304588A1

## CPC

- C07D 487/04: Ortho-condensed systems
- C07C 215/30: containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
- C07D 207/08: with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D 207/12: Oxygen or sulfur atoms
- C12P 17/10: Nitrogen as only ring hetero atom
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The application is directed to efficient and economical processes as described in more detail below for the preparation of the beta 3 agonists of the formula of I-7 and intermediate compounds that can be used for making these agonists. The present disclosure relates to a process for making beta-3 agonists and intermediates using ketoreductase (KRED) biocatalyst enzymes and methods of using the biocatalysts.

## Claims

### Claim at position 1

-18. (canceled)

### Claim 19

A process of making compound I-6:
comprising:
(a) coupling compound I-4:
with compound A-1:
in the presence of a catalyst to produce compound I-5(a), followed by deprotecting in situ with an acid to produce compound I-5(b) as a salt:
where RN=P1 or 1-5(b), where RN=H,
(b) cyclizing the salt of compound I-5(b) to produce compound I-6-1:
(c) reducing compound I-6-1 in the presence of a catalyst to produce compound I-6:
wherein P1 is selected from the group consisting of Ac, Bn, Boc, Bz, Cbz, DMPM, FMOC, Ns, Moz, and Ts;
Y is selected from the group consisting of CI, I, Br, and OTf; and
R is selected from the group consisting of H, TMS, TES, TBDMS, TIPS and TBDPS.

### Claim 20 (depends on 19)

The process of claim 19, wherein the reaction in step (a) is carried out in the presence of a solvent selected from the group consisting of THF, IPA, MeOH, EtOH, n-PrOH, NMP, DMF, DMAc, MTBE, CH2Cl2, MeCN, Me-THF, methyl cyclopentyl ether, toluene, and combinations thereof.

### Claim 21 (depends on 19)

The process of claim 19, wherein the reaction product in step (a) is isolated as an HCl salt.

### Claim 22 (depends on 19)

The process of claim 19, wherein step (b) is conducted in the presence of a base selected from the group consisting of Et3N, i-Pr2NEt, i-Pr2NH, pyridine, lutidine, N-methyl morpholine, t-BuOK, t-BuONa, t-BuOLi, NaH, NaHMDS, LiHMDS, and KHMDS.

### Claim 23 (depends on 19)

The process of claim 19, wherein compound I-6-1 is not isolated.

### Claim 24 (depends on 19)

The process of claim 19, wherein step (c) is conducted in the presence of hydrogen gas.

### Claim 25 (depends on 19)

The process of claim 19, wherein the base in step (b) is i-Pr2NEt.

### Claim 26

A crystalline HCl salt form of Compound I-5(b), wherein Compound I-5(b) has the chemical structure:

### Claim 27

A racemic mixture of Compound I-3, Compound I-3 having the chemical structure:
wherein P1 is selected from the group consisting of Ac, Bn, Boc, Bz, Cbz, DMPM, FMOC, Ns, Moz, and Ts.
